文献速递MDS 与骨髓增殖性肿瘤血栓与止血

骨髓增殖性肿瘤中NETosis水平升高但与血栓事件无关

Increased levels of NETosis in myeloproliferative neoplasms are not linked to thrombotic events.
PubMed 文献 · Blood Adv · 2021-01-01

该研究在103例费城染色体阴性骨髓增殖性肿瘤(MPN)患者和28名健康供者中,用离子霉素体外诱导NETosis并以ELISA核小体释放法和荧光染色定量,发现MPN患者NETosis水平明显高于健康供者,JAK2 V617F、外显子12或CALR突变与NET形成增加相关,但NETosis率与JAK2等位基因负荷、血栓栓塞史或其他血栓风险因素均无关。

要点

  • MPN患者体外诱导的NETosis水平明显高于健康供者。
  • JAK2 V617F、外显子12或CALR突变与NET形成增加相关。
  • NETosis率与血栓栓塞史、JAK2等位基因负荷及白细胞增多等风险因素无关。

核心结论

  • MPN的遗传驱动突变促进NETosis诱导,但NETosis率未转化为血栓栓塞并发症等重要临床终点。
  • NETosis可能促进血栓形成,但并非MPN相关血栓形成的唯一决定因素。

研究设计与样本

  • 研究纳入103例MPN患者和28名健康供者,用离子霉素体外诱导NETosis。
  • 以ELISA核小体释放法和游离DNA荧光染色定量NETosis,并与MPN亚型、突变状态、实验室变量、血栓史和治疗类型做相关分析。

主要发现

  • MPN患者触发后的NETosis水平明显高于健康供者。
  • JAK2 V617F或外显子12阳性以及CALR突变与NET形成增加相关。
  • JAK2等位基因负荷、血栓栓塞并发症史及其他血栓风险因素(如白细胞增多)均与NETosis率无关。
  • 所分析的实验室参数及治疗类型均未显著影响NETosis形成率。

临床怎么用

  • NETosis不宜单独作为MPN相关血栓风险的判定指标。
  • 对MPN患者评估血栓风险时仍需结合已知临床风险因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Morbidity and mortality of Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) are mainly determined by thromboembolic complications. Thrombus formation is facilitated by a neutrophil-specific form of cell death linked to neutrophil extracellular trap (NET) formation (NETosis). Preclinical and clinical data suggested a potential link between NETosis and thrombosis in MPNs. In this study, we aimed to define the impact of NETosis on clinical end points in a large MPN cohort. NETosis was induced in vitro by ionomycin and quantified by enzyme-linked immunosorbent assay-based nucleosome release assays as well as fluorescent staining of free DNA in samples from 103 MPN patients and 28 healthy donors. NETosis rate was correlated with a broad set of clinical data, such as MPN subtype, mutational status, laboratory variables, history of thrombotic events, and treatment types. Triggered NETosis levels were clearly higher in MPN patients than in healthy donors. Positivity for JAK2 V617F or exon 12 as well as CALR mutations correlate with increased NET formation. However, neither JAK2 allelic burden nor history of thromboembolic complication nor the presence of other risk factors for thrombosis (eg, leukocytosis) were associated with the rate of NETosis. In addition, none of the analyzed laboratory parameters nor the type of treatment significantly impacted the rate of NETosis formation. The biology of MPNs has an impact on NET formation because genetic driver mutations favor induction of NETosis, but this does not seems to translate into important clinical end points such as thromboembolic complications. Therefore, NETosis may play a role in facilitating thrombosis, but it is not a sole causative determinant in MPN-associated thrombophilia.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Schmidt S, Daniliants D, Hiller E, et al. Increased levels of NETosis in myeloproliferative neoplasms are not linked to thrombotic events. Blood Adv. 2021. PMID: 34464975. doi:10.1182/bloodadvances.2020004061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。